Claims for Patent: 8,642,015

Summary for Patent: 8,642,015

Title:	Treatment of active infections and related compositions
Abstract:	The present invention is directed to the treatment of infections and the associated symptoms of sinusitis, rhinitis and related neurological disorders of the cranial cavity and facial tissue. More specifically, the present invention is directed to aerosols that are used to treat infections and the associated symptoms of sinusitis, rhinitis and related neurological disorders of the cranial cavity and facial tissue, compositions from which the aerosols are generated and methods of generating the aerosols. In an aerosol aspect of the present invention, an aerosol for delivery to the sinus cavity of a patient is provided. The aerosol includes at least: a) one or more compounds selected from antibiotics, antifungals, leukotriene antagonists, anti-TNF compounds, antihistamines, steroidal antiinflammatories, mucolytics, estrogen, progesterone and related hormones; and, b) water. The compounds are present in the water at a concentration ranging from 0.01 mg/kg to 1000 mg/kg, and the aerosol does not contain a surfactant.
Inventor(s):	Osbakken; Robert Scott (Camarillo, CA), Reitz; Russell N. (Camarillo, CA), Tarrant; John C. (Camarillo, CA)
Assignee:	Aerosol Science Laboratories, Inc. (Camarillo, CA)
Application Number:	13/685,528
Patent Claims:	1. A method of delivering a medication aerosol to the sinus cavity of a patient, comprising preparing a medication aerosol by passing a liquid composition through a filter, and administering the medication aerosol to a patient, wherein: the filter comprises pores; the medication aerosol and the liquid composition do not contain a surfactant; and the liquid composition comprises one or more anti-infective agents. 2. The method of claim 1, wherein said one or more anti-infective agents comprise an antibiotic or an antiviral. 3. The method of claim 2, wherein said one or more anti-infective agents comprise an antibiotic selected from the group of antibiotic classes consisting of cephalosporins, penicillins, aminoglycosides, quinolones, tetracyclines and macrolides. 4. The method of claim 2, wherein said one or more anti-infective agents comprise an antiviral selected from the group consisting of oseltamivir, acyclovir and rimantadine. 5. The method of claim 1, wherein said one or more anti-infective agents comprise an antifungal selected from the group consisting of amphotericin B, fluconazole, itraconazole and liposomal amphotericin. 6. The method of claim 1, wherein the filter pores range in size from 1 .mu.m to 6 .mu.m. 7. The method of claim 6, wherein the filter pores are a consistent size within the range from 1 .mu.m to 6 .mu.m. 8. The method of claim 6, wherein the filter pores are placed such that the distance between filter pore centers ranges from 15 .mu.m to 150 .mu.m. 9. The method of claim 1, wherein said liquid composition further comprises one or more selected from the group consisting of a leukotriene antagonist, an antihistamine, a steroidal anti-inflammatory, a mucolytic, an anti-TNF compound, estrogen, and progesterone. 10. The method of claim 1, wherein said liquid composition further comprises a leukotriene antagonist selected from the group consisting of montelukast and zafirlukast. 11. The method of claim 1, wherein said liquid composition further comprises azelastin. 12. The method of claim 1, wherein the liquid composition further comprises a steroidal antiinflammatory selected from the group consisting of budesonide, betamethasone and mometasone. 13. The method of claim 1, wherein the liquid composition further comprises a mucolytic selected from the group consisting of acetylcysteine and dornase alpha. 14. The method of claim 1, wherein the liquid composition further comprises an anti-TNF compound selected from the group consisting of infliximab, etanercept, adalimumab. 15. The method of claim 1, wherein a pressure is applied to the liquid composition to pass the liquid composition through the filter. 16. The method of claim 15, wherein the applied pressure is between 30 psi and 300 psi. 17. The method of claim 15, wherein the applied pressure is generated by a pump or by a mechanical piston. 18. A medication aerosol comprising an anti-infective agent for delivery to the sinus cavity of a patient, prepared by passing a liquid composition comprising an anti-infective agent through a filter comprising pores, thereby forming the aerosol, wherein the medication aerosol comprises an anti-infective agent and water, with the anti-infective agent present in the water at a concentration ranging from 0.01 mg/ml to 1000 mg/ml; and wherein the liquid composition and medication aerosol do not contain a surfactant. 19. The medication aerosol of claim 18, wherein said one or more anti-infective agents comprise an antibiotic or an antiviral. 20. The medication aerosol of claim 19, wherein the antibiotic is selected from the group of antibiotic classes consisting of cephalosporins, penicillins, aminoglycosides, quinolones, tetracyclines and macrolides. 21. The medication aerosol of claim 19, wherein the antiviral is selected from the group consisting of oseltamivir, acyclovir and rimantadine. 22. The medication aerosol of claim 19, wherein said one or more anti-infective agents comprise an antifungal selected from the group consisting of amphotericin B, fluconazole, itraconazole and liposomal amphotericin. 23. The medication aerosol of claim 18, wherein the filter pores range in size from 1 .mu.m to 6 .mu.m. 24. The medication aerosol of claim 23, wherein the filter pores are a consistent size within the range from 1 .mu.m to 6 .mu.m. 25. The medication aerosol of claim 23, wherein the filter pores are placed such that the distance between filter pore centers ranges from 15 .mu.m to 150 .mu.m. 26. The medication aerosol of claim 18, wherein said liquid composition further comprises one or more selected from the group consisting of a leukotriene antagonist, an antihistamine, a steroidal anti-inflammatory, a mucolytic, an anti-TNF compound, estrogen, and progesterone. 27. The medication aerosol of claim 18, wherein said liquid composition further comprises a leukotriene antagonist selected from the group consisting of montelukast and zafirlukast. 28. The medication aerosol of claim 18, wherein said liquid composition further comprises azelastin. 29. The medication aerosol of claim 18, wherein said liquid composition further comprises an anti-TNF compound selected from the group consisting of infliximab, etanercept, adalimumab. 30. The medication aerosol of claim 18, wherein said liquid composition further comprises a steroidal antiinflammatory selected from the group consisting of budesonide, betamethasone and mometasone. 31. The medication aerosol of claim 18, wherein said liquid composition further comprises a mucolytic selected from the group consisting of acetylcysteine and dornase alpha. 32. The medication aerosol of claim 18, wherein a pressure is applied to the liquid composition to pass the liquid composition through the filter. 33. The medication aerosol of claim 32, wherein the applied pressure is between 30 psi and 300 psi. 34. The medication aerosol of claim 32, wherein the applied pressure is generated by a pump or by a mechanical piston.

Details for Patent 8,642,015

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REMICADE	infliximab	For Injection	103772	08/24/1998		2025-12-15
Immunex Corporation	ENBREL	etanercept	For Injection	103795	11/02/1998		2025-12-15
Immunex Corporation	ENBREL	etanercept	For Injection	103795	05/27/1999		2025-12-15